4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one
• 英文别名: 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
• 化学式: C18H22FN7O6S
• 分子量: 483.5
• InChiKey: UMXLOLALOLDSJZ-JDUXRADGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.67
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  202
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• Therapeutic compounds
  申请人：Gilead Sciences, Inc.

  公开号：US10202353B2

  公开（公告）日：2019-02-12

  Compounds of Formula I, or salts thereof, are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, intermediates useful for preparing compounds of Formula I and therapeutic, methods for treating a Retroviridae viral infection, in particular infection caused by the HIV virus.

  公开了式 I 化合物或其盐类。还公开了包含式 I 化合物的药物组合物、制备式 I 化合物的工艺、用于制备式 I 化合物的中间体以及治疗逆转录病毒科病毒感染（尤其是由 HIV 病毒引起的感染）的方法。
• PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTI-RETROVIRAL DRUG AND A PHARMACOKINETIC ENHANCER
  申请人：Cipla Limited

  公开号：EP3413913A1

  公开（公告）日：2018-12-19
• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc..

  公开号：US20160368881A1

  公开（公告）日：2016-12-22

  Compounds of Formula I: or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, intermediates useful for preparing compounds of Formula I and therapeutic, methods for treating a Retroviridae viral infection, in particular infection caused by the HIV virus.
• PHARMACEUTICAL COMPOSITIONS
  申请人：CIPLA LIMITED

  公开号：US20170232020A1

  公开（公告）日：2017-08-17

  An oral or injectable pharmaceutical composition is provided for treating diseases caused by retroviruses or hepatitis B viruses. The composition comprises a therapeutically effective amount of at least one anti-retroviral drug and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof. Methods and kits are also provided.
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTI-RETROVIRAL DRUG AND A PHARMACOKINETIC ENHANCER<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT UN MÉDICAMENT ANTIRÉTROVIRAL ET UN POTENTIALISATEUR PHARMACOCINÉTIQUE
  申请人：CIPLA LTD

  公开号：WO2017138022A1

  公开（公告）日：2017-08-17

  An oral or injectable pharmaceutical composition is provided for treating diseases caused by retroviruses or hepatitis B viruses. The composition comprises a therapeutically effective amount of at least one anti-retroviral drug and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof. Methods and kits are also provided.